Quantcast

Latest Sulfoxides Stories

2010-10-18 16:00:33

Baclofen, esomeprazole investigated as treatments The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep"”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep"”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas. Functional dyspepsia is a...

2010-09-22 11:29:00

DEXILANT is the First Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology MISSISSAUGA, ON, Sept. 22 /PRNewswire/ - To view this Social Media Release, please enter the following address in your web browser. http://smr.newswire.ca/en/takeda-canada-inc/patients-living-with-gerd-now-have-a-new-treatment SOURCE Takeda Canada Inc.

2010-07-27 07:00:00

PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor (PPI), a commonly prescribed category of heartburn medications. The study will examine the impact that the PPI, Prevacid® (lansoprazole), has on the effect of two different anti-platelet agents,...

2010-07-01 07:00:00

WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus' Zegerid®. Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing...

2010-07-01 06:25:00

CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg...

2010-06-02 15:30:00

FRAZER, Pa., June 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL® (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal. The analysis of the data showed that treatment with armodafinil did not lessen the severity of the negative...

2010-05-25 14:53:00

Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk. (Logo:...

e1c5d5999898b09b579ed6902146d9e11
2010-05-11 06:45:00

The results of several studies released on Monday are suggesting that certain heartburn medicines may be doing more harm than good. Serious side effects could arise and it has been recommended that people use the drugs with caution. AstraZeneca's Nexium and Prilosec brands are among the drugs that could be harmful to health. While the drugs are helpful to the right patients, they can increase the risk of fractures in post-menopausal women and cause bacterial infections in many patients,...

2010-05-05 08:00:00

NEW ORLEANS, May 5 /PRNewswire/ -- What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX(TM) (dexlansoprazole). The medical community...

2010-04-30 22:01:00

WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO(TM)( )(naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.(1) VIMOVO, co-developed by POZEN Inc....


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related